Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-881 versus HYQVIA pharmacokinetics crossover study in primary immunodeficiency diseases
NL-OMON59354Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of TAK-881 and Human normal immunoglobulin G in Immunogenetic disorder and Primary antibody deficiency (PAD) (3 arms), sponsored by Takeda. Primary endpoint: AUC0-τ,ss based on total IgG levels. Started Sep 2024; status: completed.
02
Drugs
TAK-881Human normal immunoglobulin G
03
Conditions
Immunogenetic disorderPrimary antibody deficiency (PAD)
Beyond the preview
Go deeper on NL-OMON59354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59354.